The ADDF provides funding to academic centers and biotechs from around the world that are advancing therapeutic and biomarker development for Alzheimer’s and related dementias. Learn more about our venture philanthropy funding model and areas of focus.
The aim of this RFP is to further develop and validate established biomarkers for which there is a clear clinical need in Alzheimer’s disease and related dementias. This RFP prioritizes biomarkers with a defined context of use, a clear advantage over other relevant biomarkers, and a path to commercialization and/or clinical use.
Specifically, this RFP focuses on:
- Developing novel PET ligands for clinical trials
- Supporting novel CSF biomarkers
- Validating innovative MRI approaches in larger cohorts
- Developing novel measures of functional activity such as EEG
Peripheral biofluids and digital/ocular approaches are supported through the Diagnostics Accelerator RFP.
Novel biomarkers of neuroinflammation, synaptic integrity, autophagy and TDP-43 are high priority. Other target areas of interest include:
- Neuronal loss
- Vascular injury and blood-brain barrier integrity
- Mitochondria and metabolic function
- Protein misfolding
- Oxidative stress
- White matter changes
- Lewy body dementia
- Other novel targets supported by compelling biological rationale and connection to disease
The ADDF has limited interest in CSF measures of amyloid and tau.
Review the Application Instructions for steps on applying.
For inquiries, please contact:
ADDF Grants and Mission-Related Investments Team
grants@alzdiscovery.org
Visit funding web page
(https://www.alzdiscovery.org/research-and-grants/funding-opportunities/biomarkers)
